GALECTIN THERAPEUTICS INC - COM NEW (GALT)

CUSIP: 363225202

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class
Equity / COM NEW
Total 13F shares
9,406,177
Share change
-855,139
Total reported value
$20,414,792
Put/Call ratio
214%
Price per share
$2.17
Number of holders
68
Value change
-$1,888,720
Number of buys
19
Number of sells
33

Quarterly Holders Quick Answers

What is CUSIP 363225202?
CUSIP 363225202 identifies GALT - GALECTIN THERAPEUTICS INC - COM NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q1 2021

As of 31 Mar 2021, GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by 68 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 9,406,177 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, ADVISOR GROUP HOLDINGS, INC., GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, NORTHERN TRUST CORP, RENAISSANCE TECHNOLOGIES LLC, Cutter & CO Brokerage, Inc., Nuveen Asset Management, LLC, and JPMORGAN CHASE & CO. This page lists 68 institutional shareholders reporting positions in this security for the Q1 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.